Showing results (161-170 of 242) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|December 21, 2021
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trialCarol Aghajanian, Elizabeth M Swisher, Aikou Okamoto, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
The American Journal of Surgical Pathology|July 22, 2017
Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is RequiredJustine L Pickett, Angela Chou, Juliana A Andrici, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
The Oncologist|June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit StudyFelicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
JAMA Network Open|August 9, 2024
Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following ChemotherapyTiffany Li, Hannah C Timmins, Fawaz M Mahfouz, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Gynecologic Oncology|November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.
Journal for Immunotherapy of Cancer|June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trialYoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
Pageof 25